Brief: Active Biotech Says Patent For Tasquinimod In Myelofibrosis Granted In Europe
21/05/2025 07:33
May 21 (Reuters) - Active Biotech AB publ ACTI.ST: ACTIVE BIOTECH ANNOUNCES PATENT FOR TASQUINIMOD IN MYELOFIBROSIS GRANTED IN EUROPE PATENT, WITH EUROPEAN PATENT NUMBER, 4185292 PROVIDES PROTECTION AND MARKET EXCLUSIVITY IN STRATEGIC EUROPEAN MARKETS THROUGH 2041 Source text: ID:nMFN1chlbc Further company coverage: ACTI.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Active Biotech AB publ
See all newsBrief: Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Brief: Active Biotech Reports Q2 Operating Profit Of SEK -10.2 Mln
Brief: Active Biotech Expands U.S. Collaboration
Brief: Active Biotech Gets Approval To Resume Enrolment In Hovon 172 MF Study
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million